All Posts Tagged With: "RDY"
(AZN) US Court Rejects AstraZeneca’s Case
Recently, AstraZeneca (AZN) announced that US District Court for the District of Columbia has dismissed the lawsuit filed by the company against the US Food and Drug Administration (FDA).
AstraZeneca...
(TEVA) Teva Pharmaceutical Industries Active on the Generics Front
Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic...
(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor
November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of...
(ISR) IsoRay’s GliaSite Gets Final Nod
IsoRay Inc (ISR), which makes the Cesium-131 internal radiation therapy (brachytherapy) isotope, has crossed the last regulatory hurdle for its GliaSite radiation therapy system, a balloon catheter used in...
(RDY) Dr. Reddy’s Laboratories Continues to Grow
Dr. Reddy’s Laboratories (RDY) reported second quarter fiscal 2012 earnings per American Depositary Share (ADS) of 40 cents, significantly above the year-ago earnings of 30 cents per ADS. Higher revenues...
(RDY) Dr. Reddy’s Laboratories Earns FDA Approval for Generic
Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic...
(RDY) Dr. Reddy’s Laboratories Launches Generic Levaquin
Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Johnson & Johnson’s (JNJ) antibiotic drug,...
(ISR) IsoRay Begins Prostate Cancer Trial
Medical isotope maker IsoRay Inc (ISR) has initiated a new combination therapy study using its Cesium-131 (an isotope) internal radiation therapy (“brachytherapy”) and external beam radiation. The study...
(RDY) Dr. Reddy’s Laboratories Announces FDA Warning Letter
Dr. Reddy’s Laboratories (RDY) recently announced that the US Food and Drug Administration (FDA) issued a four item warning letter regarding the company’s chemical manufacturing facility at Cuernavaca,...
(RDY) Dr. Reddy’s Laboratories Continues to Grow
Dr. Reddy’s Laboratories (RDY) reported fiscal 2011 earnings per American Depositary Share (ADS) of $1.50 compared with 10 cents per ADS posted in fiscal 2010. Higher revenues and lower operating expenses...
(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares
We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per...
(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues
Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate...
(MRK) Merck in Joint Venture with Sun Pharma
Merck & Co., Inc. (MRK) recently announced that it is setting up a joint venture (JV) with Indian multinational pharma company, Sun Pharmaceutical Industries Ltd. The joint venture is for the development,...
(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were...
(RDY) Dr Reddy’s Laboratories Reports Respectable Second Quarter 2011 Earnings
Dr Reddy’s Laboratories (RDY) reported second quarter fiscal 2011 earnings per American Depository Share (ADS) of 40 cents compared with earnings of 30 cents in the year-ago period. Higher gross margin led...
(PFE) Pfizer and Biocon Enter Gloabal Diabetes Deal
Pfizer (PFE) recently entered into a global agreement with Indian biotech company Biocon, for certain diabetes biosimilars. The deal relates to the global commercialization of biosimilar versions...
(ABT) Abbott Labs Announces Aquisition of Indian Company Piramal Healthcare
Abbott Labs (ABT) recently completed its acquisition of Indian company Piramal Healthcare Ltd.’s Healthcare Solutions business (Domestic Formulations) for $3.8 billion. In addition to an...
(FRX) Forest Laboratories Settles Patent Fight
Forest Laboratories Inc. (FRX) and partner Merz GmbH & Co. KGaA recently entered into a patent litigation settlement agreement with about 10 companies that were seeking to launch their...
(ABT) Abbott Laboratories to Buy Piramal Healthcare Unit
Abbott Laboratories (ABT) is all set to acquire Indian company Piramal Healthcare Ltd.’s Healthcare Solutions business (Domestic Formulations) for $3.72 billion. Per the terms of the definitive...
(WPI) Watson Pharmaceuticals Sees 16 Analysts Raising Fourth Quarter Estimates
Watson Pharmaceuticals, Inc. (WPI) reports fourth-quarter results on February 23, with the current Zacks Consensus Estimate at 72 cents per share. Estimates appear to be modestly up, with one of the 16 analysts...
(RDY) Dr Reddy’s Laboratories Reports Earnings and Slashes Guidance
Recently, Dr Reddy’s Laboratories (RDY) announced third quarter loss per ADS of 70 cents after a write-down of $174 million associated with its betapharm business in Germany and other intangibles. Excluding...
(WPI) Watson Pharmaceuticals Set to Top Expectations
Watson Pharmaceuticals, Inc. (WPI) recently announced that it expects 2009 earnings to meet or exceed guidance provided by the company in Nov. 2009. The company had earlier guided towards earnings in the range...
(GSK) GlaxoSmithKline Exercises Drug Option
Recently, GlaxoSmithKline (GSK) exercised its option to obtain exclusive license regarding further development and commercialization of ChemoCentryx’s Traficet-EN, a specific CCR9 antagonist. The drug...
(WPI) Watson Pharmaceuticals Coverage Initiated at Neutral
We recently initiated coverage on Watson Pharmaceuticals, Inc. (WPI) with a “Neutral” recommendation and a target price of $42. The company enjoys a strong position in the generics market. We...
(PFE) Pfizer Joins With Strides Arcolab For Off-Patent Generics in the U.S.
Pfizer, Inc. (PFE) recently joined hands with Indian company Strides Arcolab for the commercialization of off-patent sterile injectable and oral products in the United States. As per the agreement, these products...
(GSK) GlaxoSmithKline Reports Higher Revenues
GlaxoSmithKline, plc (GSK) reported third quarter income of 92 cents per American Depository Share (ADS), 3 cents below the Zacks Consensus Estimate. The company reported earnings of 94 cents in the year-ago...
(PRX) Top Performer for Thurs: Par Pharmaceutical Companies
Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session.
In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks...
(GSK) GlaxoSmithKline Plc Expands Presence in China With Jiangsu Walvax Biotech Joint Venture
GlaxoSmithKline Plc (GSK) continues to expand its presence in China and other emerging markets. Earlier this week, the company formed a joint venture (JV) with Chinese company, Jiangsu Walvax Biotech Company, for the development and production of pediatric...
(GSK) Pharma Majors to Gain from India
All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents...
(SGP) Schering-Plough Settles Lawsuits – Analyst Blog
Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex.
This signals the end of...